LENZ director buys 5,592 shares in open market

LENZ Therapeutics director George Jeffrey P. reported an open-market purchase of common stock.

Rhea-AI Filing Summary

LENZ Therapeutics director George Jeffrey P. reported an open-market purchase of common stock. On March 27, 2026, he bought 5,592 shares of LENZ Therapeutics, Inc. at a weighted average price of $8.9217 per share, within a price range of $8.80 to $9.12.

Following this transaction, he directly holds 5,592 shares of LENZ common stock. The filing notes that the total represents multiple individual trades aggregated into the reported weighted average price.

Insider Trade Summary

Net Buyer: 5,592 shares

Net Buy 1 txn

Insider George Jeffrey P.

Role Director

Bought 5,592 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,592	$8.9217	$50K

Holdings After Transaction: Common Stock — 5,592 shares (Direct)

Footnotes (1)

1. F1. Represents the weighted average share price of an aggregate total of 5,592 shares purchased in the price range of $8.80 to $9.12 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LENZ (LENZ) disclose in this Form 4?

LENZ Therapeutics disclosed that director George Jeffrey P. bought 5,592 shares of common stock. The purchase was an open-market transaction at a weighted average price of $8.9217 per share, reflecting multiple trades within a stated price range.

How many LENZ (LENZ) shares did the director buy and at what price?

The director purchased 5,592 LENZ Therapeutics shares in the open market. The filing reports a weighted average price of $8.9217 per share, based on individual trades executed between $8.80 and $9.12 during the transaction date.

What is the director’s total LENZ (LENZ) ownership after this transaction?

After the reported purchase, director George Jeffrey P. directly owns 5,592 shares of LENZ Therapeutics common stock. This total matches the number of shares acquired in the transaction, indicating the position reported is entirely from this recent open-market purchase.

Was the LENZ (LENZ) insider trade an open-market purchase?

Yes. The Form 4 classifies the transaction as an open-market purchase of common stock. The director bought 5,592 shares at a weighted average price of $8.9217, with trades executed across a price range from $8.80 to $9.12 per share.

What price range did LENZ (LENZ) shares trade in for this insider purchase?

The filing states that the 5,592 shares were purchased within a price range of $8.80 to $9.12 per share. The reported transaction price of $8.9217 represents the weighted average of those individual trades executed by the director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/30/2026 - 08:47 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

George Jeffrey P.

(Last) (First) (Middle)

C/O LENZ THERAPEUTICS, INC.

201 LOMAS SANTA FE, SUITE 300

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/27/2026		P		5,592	A	$8.9217(1)	5,592	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average share price of an aggregate total of 5,592 shares purchased in the price range of $8.80 to $9.12 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Remarks:

	/s/ Daniel R. Chevallard, as Attorney-in-Fact	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)